Search clinical trials for: Monoclonal Antibody (Humanized Anti-CD52)

Total 2591 results

Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma

Eosinophilic Asthma

United States, Australia, Belgium, Chile, Colombia, Czechia, Denmark, Hungary, Israel, Malaysia, New Zealand, Philippines, Poland, Russian Federation, South Africa, Sweden, Thailand
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma

Eosinophilic Asthma

United States, Argentina, Brazil, Canada, France, Mexico, Germany, Greece, Korea, Republic of, Peru, Romania, Russian Federation, Slovakia, Taiwan, Ukraine
Bio-Thera Solutions

Terminated

Assessment of Safety and Preliminary Efficacy With BAT6021 in Solid Tumor Patients in China

Solid Tumor

China
Beijing Mabworks Biotech Co., Ltd.

Recruiting

A Clinical Study of MIL95 in Advanced Malignancies.

Advanced Malignancies

China
Shanghai Henlius Biotech

Not yet recruiting

A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of HLX35 in Combination With HLX10 in Patients With Advanced or Metastatic Solid Tumors

Solid Tumor, Adult
National Cancer Institute (NCI)

Completed

Alemtuzumab With or Without Methotrexate and Mercaptopurine in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia

Recurrent Childhood Acute Lymphoblastic Leukemia

United States
Shenyang Sunshine Pharmaceutical Co., LTD.

Completed

A Trial With Humanized TNFα Monoclonal Antibody Injection by Single Dose and Dose Escalation in Healthy Subjects

Rheumatoid Arthritis

China
InflaRx GmbH

Completed

Clinical Assessment of Safety and Tolerability of the New Monoclonal Humanized Antibody CaCP29

Drug Safety

Germany
Sanofi

Completed

A Study to Test if SAR443809 is Tolerated and Safe When Taken as a Single Dose in Healthy Adults

Paroxysmal Nocturnal Hemoglobinuria

United States
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...

Not yet recruiting

A Phase II Study for 609A in the Treatment of Advanced Undifferentiated Pleomorphic Sarcoma

Sarcoma, Soft Tissue

China
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic Asthma

Eosinophilic Asthma

United States, Belgium, Colombia, Hungary, Israel, Poland, Sweden, Argentina, Brazil, Canada, France, Mexico, Netherlands
M.D. Anderson Cancer Center

Active, not recruiting

Itacitinib and Alemtuzumab in Treating Patients With T-Cell Prolymphocytic Leukemia

Recurrent T-Cell Prolymphocytic Leukemia | T-Cell Prolymphocytic Leukemia

United States
Bio-Thera Solutions

Active, not recruiting

Evaluating the Safety, Tolerability, and Pharmacokinetics of BAT1006

Advanced Solid Tumor

China
Shanghai Pharmaceuticals Holding Co., Ltd

Completed

B002 in Patients With HER2-positive Breast Cancer (B002-101)

Metastatic Breast Cancer | Recurrent Breast Cancer

China
Shanghai Junshi Bioscience Co., Ltd.

Unknown

Tolerability and Pharmacokinetics of Toripalimab in Combination With Axitinib in Patients With Kidney Cancer and Melanoma

Advanced Melanoma | Kidney Cancer Stage Iv

China
Shanghai Junshi Bioscience Co., Ltd.

Unknown

Safety and Efficacy of Toripalimab for Patients With Locally Advanced or Metastatic Bladder Urothelial Carcinoma

Bladder Urothelial Carcinoma

China
Shanghai Junshi Bioscience Co., Ltd.

Unknown

Safety and Efficacy of Recombinant Humanized Anti-PD-1 mAb for Patients With Locally Advanced or Metastatic Melanoma

Metastatic Melanoma | Advanced Melanoma

China
Huabo Biopharm Co., Ltd.

Recruiting

A Study of HB0025 Injection in Patients With Advanced Renal Cancer

Renal Cancer

China
Shanghai Zhangjiang Biotechnology Limited Company

Suspended

Phase II Clinical Trial of Alemtuzumab to Treat B-cell Chronic Lymphocytic Leukemia (CLL004)

B-cell Chronic Lymphocytic Leukemia

China
Beijing Mabworks Biotech Co., Ltd.

Completed

A Study of MIL62 in Treatment of CD20 Positive B-cell Lymphomas

CD20-positive B Cell Non-Hodgkin Lymphoma

China
Shanghai Mabgeek Biotech.Co.Ltd
The Second Hospital of Anhui Medical University

Active, not recruiting

Clinical Study of MG-K10 Humanized Monoclonal Antibody Injection in Healthy Adult Subjects

Pharmacokinetics

China
United BioPharma

Recruiting

A Study to Evaluate the Pharmacodynamics, Pharmacokinetics, Safety, and Efficacy of UB-221 IV Infusion as an add-on Therapy in Patients With Chronic Spontaneous Urticaria

Chronic Spontaneous Urticaria

Taiwan
OncoMed Pharmaceuticals, Inc.

Completed

A Phase 1a/b Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of OMP-131R10

Refractory Solid Tumors | Advanced Relapsed Tumors

United States
Shanghai Junshi Bioscience Co., Ltd.

Completed

Safety and Tolerability of Recombinant Humanized Anti-PD-1 Monoclonal Antibody for Patients With Advanced Breast Cancer

Breast Cancer

China
Beijing Mabworks Biotech Co., Ltd.

Recruiting

A Clinical Study of MIL93 in Solid Tumors.

Advanced Malignancies

China
Memorial Sloan Kettering Cancer Center
Y-mAbs Therapeutics; Band of Parents

Completed

Humanized 3F8 Monoclonal Antibody (Hu3F8) in Patients With High-Risk Neuroblastoma and GD2-Positive Tumors

Neuroblastoma

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI); Actinium Pharmaceuticals

Completed

Targeted Atomic Nano-Generators (Actinium-225-Labeled Humanized Anti-CD33 Monoclonal Antibody HuM195) in Patients With Advanced Myeloid Malignancies

Leukemia | Myelodysplastic Syndrome

United States
Shanghai Huaota Biopharmaceutical Co., Ltd.

Completed

A Study to Evaluate Multi-dose of HB0034 in Healthy Adult Participants

Healthy

New Zealand
Tracon Pharmaceuticals Inc.

Completed

Phase 1, Open-label, Dose Escalation Study of TRC093, in Patients With Locally Advanced or Metastatic Solid Tumors

Cancer | Neoplasm Metastasis

United States
Gilead Sciences

Terminated

Study of Epratuzumab (hLL2) in Patients With Waldenstrom's Macroglobulinemia

Waldenstrom Macroglobulinemia

United States
Shanghai Junshi Bioscience Co., Ltd.

Completed

Study of JS001 in Participants With Advanced Solid Tumors

Solid Tumors

China
Livzon Pharmaceutical Group Inc.

Completed

LZM009 to Treat Patients With Advanced Solid Tumors

Solid Tumor

United States
Beijing Mabworks Biotech Co., Ltd.

Recruiting

Treatment of Advanced and Metastatic Solid Tumors With MIL97

Advanced or Metastatic Solid Tumor

China
Beijing InnoCare Pharma Tech Co., Ltd.

Active, not recruiting

A Study of MIL62 Combined With Orelabrutinib for the Treatment of R/R CD20+B Cell Lymphoma

B-cell Lymphoma Refractory | B-cell Lymphoma Recurrent

China
ImmuneMed, Inc.

Completed

Safety, Tolerability, Pharmacokinetic Characteristics of hzVSF-v13 in Healthy Male Volunteers

Healthy

Korea, Republic of
Xiaoming Gong

Completed

Phase II Trial of VDJ001 in Patients With Moderate-to-severe Active Rheumatoid Arthritis

Rheumatoid Arthritis

China
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

A Clinical Study to Evaluate the Efficacy and Safety of Subcutaneous JS005 Injection in the Treatment of Adults With Moderate to Severe Chronic Plaque Psoriasis

Moderate to Severe Chronic Plaque Psoriasis

China
Zhejiang Cancer Hospital

Completed

Radiation Plus Concurrent Nimotuzumab in Elderly Patients With Locoregionally Advanced Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe Asthma

Eosinophilic Asthma

United States
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...

Recruiting

A Phase Ib/II Study of Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection in Chinese Participants With Acute Gout

Acute Gout

China
United BioPharma

Not yet recruiting

Study for Evaluation of the Safety, Pharmacokinetics, and Antiviral Activity of UB-421 Subcutaneous Formulation in HIV Infected Adults

HIV-1-infection
Shanghai Junshi Bioscience Co., Ltd.
Iqvia Pty Ltd; TopAlliance Biosciences, Inc.

Active, not recruiting

Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies

Advanced Malignancies

United States
Shanghai Junshi Bioscience Co., Ltd.

Unknown

Safety and Tolerability of Recombinant Humanized Anti-PD-1 Monoclonal Antibody Toripalimab for Patients With Advanced Solid Tumors

Melanoma | Urological Cancer

China
Peking University

Unknown

Trial of Surufatinib Combined With JS001 in the Treatment of Advanced Solid Tumors

Solid Tumor

China
National Cancer Institute (NCI)

Completed

Bevacizumab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

B-cell Chronic Lymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia

United States
Huabo Biopharm Co., Ltd.

Completed

A Study of Injection HB0017 in Adult Healthy Volunteers

Healthy Subjects

New Zealand
Biocad

Completed

First-in-human Study to Evaluate Safety, Tolerability and Pharmacokinetics of Various Doses of BCD-085 in Healthy Subjects

Healthy
RemeGen Co., Ltd.

Completed

A Open-label, Single-arm, Multicenter, Phase II Study of RC48-ADC to Evaluate the Efficacy and Safety of Subjects With HER2 Overexpressing Locally Advanced or Metastatic Urothelial Cancer

Urothelial Carcinoma

China
Shanghai Junshi Bioscience Co., Ltd.
Sponsor GmbH

Recruiting

A Clinical Study of JS005 in Patients With Ankylosing Spondylitis

Ankylosing Spondylitis

China
National Cancer Institute (NCI)

Completed

Bevacizumab in Treating Young Patients With Refractory Solid Tumors

Unspecified Childhood Solid Tumor, Protocol Specific

United States

3

Subscribe